LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$22.1M, compared with -$5.64M a year earlier. Trailing-twelve-month operating income was -$46.86M.
Context
- Operating income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +53.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$22.1M-59.4% QoQ
- Last fiscal yearDec 2025
- -$30.4M+53.1% YoY
- LTMMar 2026
- -$46.86M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -291.6% | +100.0% | +391.6 pp |
| 1 year | +53.1% | +100.0% | +46.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (30.4M) USD
- Year-over-year change
- +53.1%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (30.4M) | +53.1% |
| FY2024 | 2024-12-31 | (64.83M) | -469.9% |
| FY2023 | 2023-12-31 | (11.38M) | -305.0% |
| FY2022 | 2022-12-31 | (2.81M) | — |
Operating Income vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's LTM Mar 2026 operating income of -$46.86M is the 4th highest of the 10 companies compared; the peer median is -$122.21M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $122.33M | -49.2% | — | 10.2% | |
| LTM Mar 2026 | $54.9M | +178.5% | — | — | |
| LTM Jun 2026 | -$35.14M | -117.4% | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$46.86M | — | — | — |
| LTM Mar 2026 | -$66.69M | -29.4% | — | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$122.21M | -31.3% | — | 611.0% |
| LTM Mar 2026 | -$210.04M | -140.9% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$223.08M | +18.7% | — | — |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | -$254.15M | -68.1% | — | — |
| LTM Jun 2026 | -$542.7M | -1.7% | — | 15058.2% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | -$122.21M | -31.3% | — | 611.0% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 1.35M | 7.85M | 51.17M | 16.74M |
| Selling, General & Admin | 1.46M | 3.53M | 13.66M | 13.66M |
| Operating Expenses | 2.81M | 11.38M | 64.83M | 30.4M |
| Depreciation & Amortization | 2K | 4K | 91K | 321K |
| EBITDA | (12.19M) | (1.45M) | (63.01M) | (24.88M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (2.81M) | (11.38M) | (64.83M) | (30.4M) |
| Operating Margin | — | — | — | — |
| Interest Income | 73K | 811K | 1.72M | 3.92M |
| Interest Expense | 2.15M | 4.83M | 0 | 0 |
| Other Income / Expenses | (11.54M) | 5.1M | 1.73M | 5.2M |
| Income Before Tax | (14.35M) | (6.27M) | (63.1M) | (25.2M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1K | 1K | 1K | 1K |
| Net Income | (14.35M) | (6.28M) | (63.1M) | (25.21M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (4.05) | (1.77) | (17.83) | (1.00) |
| EPS (Diluted) | (4.05) | (1.77) | (17.83) | (1.00) |
| Weighted Avg Shares | 3.54M | 3.54M | 3.54M | 25.3M |
| Weighted Avg Shares (Diluted) | 3.54M | 3.54M | 3.54M | 25.3M |
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.